Publications

Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: Report from the Garenoxacin International Bridging Study. by Jones RN, Gordon KA, Biedenbach DJ published in J. Antimicrob. Chemother. 2004; 53 (2): 258-265

In vitro activities of the novel cephalosporin LB11058 against multidrug-resistant staphylococci and streptococci. by Sader HS, Johnson DM and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 53-62

An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. by Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Nydman DR, Ip M, Ko WC, Chedid MBF, Andremont A, Klugman KP, and International Pneumococcal Study Group published in Clin. Infect. Dis. 2003; 37 (2): 230-237

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN published in Antimicrob. Agents Chemother. 2003; 47 (3): 1068-1071

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. by Bell JM, Turnidge JD, Ballow CH, Jones RN and ZAPS Regional Participants published in J. Antimicrob. Chemother. 2003; 51 (2): 339-345

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and ß-lactams tested against Gram-negative bacilli. by Sader HS, Huynh HK, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 47 (3): 547-550

Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). by Sader HS, Fritsche TR, Mutnick AH, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 47 (3): 515-525

Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: A survey of ten medical center laboratories. by India Antimicrobial Resistance Study Group, Mathai D, Rhomberg PR, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (4): 367-377

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. by Jones RN, Deshpande LM, Mutnick AJ and Biedenbach DJ published in J. Antimicrob. Chemother. 2002; 50 (6): 915-932

Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 323-326

In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY Antimicrobial Surveillance Program (1998-1999). by Bell JM, Turnidge JD, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 315-318

In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. by Anderegg TR, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (8): 2662-2664

In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci. by Anderegg TR, Biedenbach DJ and Jones RN published in J. Antimicrob. Chemother. 2002; 49 (6): 1019-1021

In vitro activity of meropenem, imipenem, piperacillin/tazobactam, ciprofloxacin, amikacin, and cefepime against P. aeruginosa and A. baumannii isolated from Brazilian intensive care units: MYSTIC Study Group (Brazil 2001). by Mendes C, Kiffer C, Oplustil C, Sinto S, Turner P, Jones RN and Hsiung A published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 165

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: Report from the SENTRY Antimicrobial Surveillance Program (1998-1999) including an in vitro evaluation of BMS284756. by Bell J, Turnidge J, Jones RN and SENTRY Regional Participants Group published in Int. J. Antimicrob. Agents 2002; 19 (2): 125-132

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons. by Pfaller MA, Jones RN, Biedenbach DJ, Beach ML published in J. Chemother. 2002; 14 (1): 13-18

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 145-147

Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: Initial development of in vitro susceptibility test methods. by Jones RN, Pfaller MA, Rhomberg PR and Walter DH. published in J. Clin. Microbiol. 2002; 40 (2): 461-465

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. by Jones RN, Biedenbach DJ and Anderegg TR published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 119-122

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: A multicentre international trial. by Jones RN, Hare RS and Sabatelli FJ published in J. Antimicrob. Chemother. 2001; 47 (1): 15-25

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. by Jones RN, Ballow CH and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2001; 40 (1-2): 59-66

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. by Jones RN, Biedenbach DJ, Johnson DM and Pfaller MA published in J. Chemother. 2001; 13 (3): 244-254

In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. by Jones RN published in J. Chemother. 2001; 13 (4): 363-376

Cefditoren in vitro activity and spectrum: A review of international studies using reference methods. by Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC and Fuchs PC published in Diagn. Microbiol. Infect. Dis. 2001; 41 (1-2): 1-14

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. by Fix AM, Pfaller MA, Biedenbach DJ, Beach ML and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (2): 141-145

In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (1): 49-53

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 40 (4): 173-177

In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. by Pfaller MA, Messer SA, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2001; 45 (10): 2862-2864

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. by Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2000; 44 (10): 2883-2886

In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997- 1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Int. J. Antimicrob. Agents. 2000; 15 (2): 111-118

Evaluation of gemifloxacin (SB-265805, LB20304a): In vitro activity against over 6,000 Gram-positive pathogens from diverse geographic areas. by Jones RN, Pfaller MA and Erwin ME published in Int. J. Antimicrob. Agents 2000; 15 (3): 227-230

In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum β-lactamase producing strains. by Deshpande L, Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2000; 15 (4): 271-275

In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: Role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group. by Lewis MT, Biedenbach DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 317-323

Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone. by Jones RN, Erwin ME, Biedenbach DJ, Johnson DM and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 227-234

In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods. by Jones RN, Barrett MS and Pfaller MA published in Clin. Microbiol. Infect. 1999; 5 (9): 577-579

Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. by Biedenbach DJ, Jones RN, Lewis MT, Croco MA, and Barrett MS published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 275-282

Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and Etest methods. by Biedenbach DJ, Croco MA, Barrett TJ and Jones RN published in Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18 (6): 428-431

In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. by Biedenbach DJ, Lewis MT and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 277-283

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 299-305

In vitro evaluation of cefepime and other broad-spectrum β-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 325-331

Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum β-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group. by Xu Y, Chen M, Biedenbach DJ, Deshpande LM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (35): 135-142

Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. by Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (8): 2005-2009

In vitro evaluation of cefepime and other broad-spectrum β-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group. by Lewis MT, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 285-290

In vitro evaluation of cefepime and other broad-spectrum β-lactams in 22 medical centers in Japan: A phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. by Lewis MT, Yamaguchi K, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 307-315

In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin. by Johnson DM and Jones RN. published in J. Antimicrob. Chemother. 1998; 42 (4): 555-557

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. by Croco MA, Biedenbach DJ, Pfaller MA, Doern GV, and Jones RN published in J. Antimicrob. Chemother. 1998; 42 (5): 672-673

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. by Cormican M, Corbett-Feeney G, Kelly S, Hughes D, Flynn J, and Jones RN published in Ir. J. Med. Sci. 1998; 167 (3): 155-159

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. by Pfaller MA, Marco F, Messer SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (4): 251-255

In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. by Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME and Hajjeh RA published in Antimicrob. Agents Chemother. 1998; 42 (12): 3242-3244